secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2023-12-21T23:59:59+00:00
Accession:  0001104659-23-128299
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma appoints Irenic's Jeremy Grant to board, enters cooperation agreement, reaffirms capital return
--------------------------------------------------------------------------------

- Jeremy Grant appointed to Board as Class II director; Board temporarily expands to 10.
- Cooperation agreement with Irenic includes standstill, voting commitments, and information sharing rights.
- Company reaffirms commitment to return all excess capital; $300M returned since mid-2022, shares reduced ~35%.
- Dr. Burton Malkiel not standing for re-election at May 2024 AGSM; Board will revert to 9 directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923128299/0001104659-23-128299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465923128299/tm2333517d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-128299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer